Last reviewed · How we verify

Graceway Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief

Graceway Pharmaceuticals, LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Aldara (imiquimod) cream, 5% Aldara (imiquimod) cream, 5% marketed TLR7 agonist TLR7 (Toll-like receptor 7) Oncology, Dermatology, Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Apotex Inc. · 1 shared drug class
  2. Elion Therapeutics, Inc. · 1 shared drug class
  3. MEDA Pharma GmbH & Co. KG · 1 shared drug class
  4. Medical University of Graz · 1 shared drug class
  5. Medical University of Vienna · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Graceway Pharmaceuticals, LLC:

Cite this brief

Drug Landscape (2026). Graceway Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/graceway-pharmaceuticals-llc. Accessed 2026-06-10.

Related